4 of 29 GLP‑1 telehealth programs have received an FDA warning letter

We track 29 online GLP-1 programs and re-read each of them every week.2 4 of them — 13.8% — are matched to an FDA warning letter addressed to the firm behind the program.1 The matches run from September 2025 to June 2026.

The FDA's GLP-1 warning letter register holds 157 letters, 110 of them addressed to online sellers.1 Only 4 attach to a program we list. The gap is not evidence that the rest were cleared: it is the difference between the whole direct-to-consumer market and the 29 programs a review site can keep verified. Read this figure as a floor on the programs we cover, never as a count of enforcement in the market.

A letter is attributed to a program only where the recipient firm can be identified as the company behind it with confidence.1 That is harder than it sounds: programs trade under a consumer brand, contract compounding to a third party, and sometimes share a corporate parent with a firm under a different name. An unmatched letter stays in the warning letter register and is counted there, not here — which means this number understates rather than overstates.

None of the matches carries a recorded resolution.1 That is close to uninformative on its own. The FDA publishes closeout letters for a minority of matters and typically more than a year after the fact, so an absent resolution is the default state of a recent letter and not a finding about the firm. What the letter does establish is that the agency put an allegation in writing and published it, on a date, against a named company.

The complete list, so the count can be checked rather than taken on trust. Names link to the page for that record where one is published.

Two inputs. The FDA's published warning letters, ingested whole and filtered to those naming a GLP-1.1 And the programs listed here, which is the glp1.health Check — our own weekly re-read of each program's price, fees, states served, pharmacy and enforcement record.2 The figure is the count of listed programs with at least one matched letter, over the count of listed programs.

The denominator is ours, and that is the honest limit of this page. It is 29 programs we list and can keep verified week by week, not a census of everyone selling a GLP-1 online. Nobody publishes that census, and a denominator we cannot check would make the percentage look authoritative while meaning nothing.

What we add to a federal file is the join and the reading, and we say so: the glp1.health Check is our own weekly re-read of the programs, and it is a separate thing from the federal data. Where a figure on this page comes from the Check rather than from an agency, the sources list below says which.

Each of these changes what the figure means. They are numbered so a quotation can name the one it breaks.

1. A warning letter is an allegation the FDA has published. It is not a court finding.
2. A letter is attributed to a program only where the named firm matches it with confidence. Unmatched letters are counted in the register, not here.
3. The denominator is the programs tracked on this site, not every GLP-1 seller in the United States.
4. Absence of a recorded resolution is common for recent letters and is not evidence of unresolved violations: the FDA publishes closeout letters for a minority of matters, typically more than a year later.